base metals investing Mesoblast Acquires Chimeric Antigen Receptor Platform Technology for Precision-Enhanced Cell Products
base metals investing Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION
base metals investing Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation
base metals investing Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation
base metals investing Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter
base metals investing Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter
base metals investing Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast
base metals investing High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD
base metals investing Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment
base metals investing FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy
